Related Experiment Video

Updated: Jul 18, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Antitumor activity of the marine natural product dibromophakellstatin in vitro

Michael Zöllinger1, Gerhard Kelter, Heinz-Herbert Fiebig

  • 1Ludwig Maximilian University, Department of Chemistry and Biochemistry, Butenandtstr. 5-13, 81377 Munich, Germany.

Bioorganic & Medicinal Chemistry Letters
|November 11, 2006
PubMed

Insights

Rac-dibromophakellstatin, a novel alkaloid, shows selective antitumor effects against various cancer cell lines in vitro. Only the naturally occurring enantiomer, (-)-dibromophakellstatin, exhibits activity, suggesting a specific mechanism of action.

Area of Science:

  • Natural Product Chemistry
  • Pharmacology
  • Oncology

Background:

  • Pyrrole-imidazole alkaloids are a class of natural products with diverse biological activities.
  • Dibromophakellstatin is a marine natural product with potential therapeutic applications.

Purpose of the Study:

  • To evaluate the in vitro antitumor activity of rac-dibromophakellstatin against a panel of human cancer cell lines.
  • To investigate the stereospecificity and structure-activity relationship of dibromophakellstatin's antitumor effects.

Main Methods:

  • Cell survival and proliferation assays were performed on 36 human cancer cell lines.
  • Chiral High-Performance Liquid Chromatography (HPLC) was used to separate enantiomers.
  • Debromination of the pyrrole moiety was conducted to assess its impact on activity.

Main Results:

  • Rac-dibromophakellstatin demonstrated selective antitumor activity, with notable sensitivity in ovarian, glioblastoma, non-small cell lung, and uterus cancer cell lines.
  • The naturally occurring (-)-dibromophakellstatin enantiomer was identified as the sole active compound.
  • Debromination of the pyrrole moiety resulted in a complete loss of antitumor activity.

Conclusions:

  • (-)-Dibromophakellstatin possesses selective antitumor properties, indicating potential for novel cancer therapies.
  • The stereochemistry and specific structural features of dibromophakellstatin are crucial for its biological activity.
  • Further research into the mechanism of action of (-)-dibromophakellstatin is warranted.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...